Biotech and Hygiene Stocks Outperform as Viva, Soft Report Double-Digit H1 Growth

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Viva Biotech (1873.HK) reported 21% year-on-year revenue growth for H1 2026, driven by two new commercialization projects at Langhua Pharmaceutical, which saw a 47% revenue surge. Despite bottom-line pressure, the stock rose 11.83% in the week of September 19, outperforming the Hang Seng Index by 140 basis points amid AI-driven CRO sector optimism.

Soft International (2569.HK) posted 25% revenue growth to CNY 549.31 million in the same period, with net profit up 9.2%. The Shishi nonwoven fabric facility expansion, set for completion in late 2026, will support 2027 production ramp-up. Rising sales expenses from digital marketing pushed margins to 34%, maintaining profitability amid sector headwinds.

The dual outperformance highlights niche strength in Hong Kong's small-cap segment, where targeted growth narratives are gaining traction. Both companies leveraged operational milestones rather than broad market trends to drive investor interest during September's volatile trading environment.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.